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Ann Anderson, Snake oil, hustlers and
hambones: the American medicine show,
Jefferson, NC, McFarland & Co., 2000,
pp. 190, illus., £30.40 (hardback 0-7864-
0800-6). Distributed in the UK by Shelwing
Ltd, 4 Pleydell Gardens, Folkestone, Kent
CT202DN.
This book is an informative and
entertaining history of the American
medicine show. The first chapter briefly
describes the European antecedents of the
medicine show, such as Italian
mountebanks, and the rest of the book
traces the evolution of the institution in
America from colonial times to the
twentieth century. These shows ranged in
size from a single performer to large-scale
wild west or variety shows, but in each case
the purpose was the same, to use some form
of entertainment to lure potential customers
and encourage them to buy the medicinal
products on sale. Mostly these products
were typical patent medicines of the period,
whether home brewed or purchased from
pharmaceutical manufacturers.
Anderson's book provides a lively and
largely accurate introduction to the subject
for the general reader. It will be of less
interest to scholars in the history of
medicine because it is drawn very heavily
from secondary sources, such as James
Harvey Young's Toadstool millionaires
(1961) and Brooks McNamara's Step right
up (1976). While she does make use of
autobiographical memoirs written by
medicine show performers and owners, such
as Violet McNeal's Four white horses and a
brass band (1947), Anderson does not cite
any manuscript sources in her notes or
bibliography.
Anderson is an actress, and her
profession is reflected in the book, which is
long on the entertainment aspects of these
shows and short on the medical aspects. Its
strength is in the detailed and fascinating
accounts of the "show business" side of the
trade, and in her efforts to relate the
performances of the medicine shows to the
broader history ofAmerican theatre.
Readers who are more interested in the
patent medicines themselves, and less in the
entertainment, are better advised to consult
the classic studies of James Harvey Young
on the subject.
The book contains some minor errors
and inconsistencies, but no more than might
be expected in an account of such broad
scope. For example, Elixir of Sulfanilamide
(which caused over a hundred deaths in the
United States in 1937) was not diethylene
glycol, but contained the latter as a solvent.
Also, Anderson's contention that Elixir of
Sulfanilamide was a prescription drug can
be challenged, since the Food and Drug
Administration had no legal basis for
classifying drugs as "prescription only"
before the passage of the 1938 Federal
Food, Drug and Cosmetic Act. On the
whole, however, this is a very readable book
which, although not contributing much that
is new to scholarship in medical history,
provides a useful overview of the interesting
phenomenon of the American medicine
show.
John Parascandola,
Rockville, MD
Edgar Jones, The business ofmedicine: the
extraordinary history ofGlaxo, a babyfood
producer, which became one ofthe world's
most successfulpharmaceutical companies,
London, Profile Books, 2001, pp. xxiii, 520,
illus., £25.00 (hardback 186197340-3).
Edgar Jones's history of Glaxo is well
produced, with beautiful colour and black-
and-white photographs, as well as
organigrams and graphs throughout the
text. It is informative on the history of the
company, especially after 1962, the end-date
for R Davenport-Hines and J Slinn's earlier
volume, Glaxo: a history to 1962
(Cambridge University Press, 1992), and the
information it provides is rich and varied.
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However, because its structure makes it
difficult to use as a research tool, and
because it presents what is essentially an
internalist account of the company's
expansion in the post-war period, its chief
value is as a work of reference.
The central thesis of the book is laid out
in the Preface. According to Jones, new
products are the life blood of all major
pharmaceutical companies. However,
Glaxo, like other British firms, realized this
relatively late, in the 1950s, when it was
drawn into two expanding therapeutic
areas, steroids and cephalosporins. Jones
attributes the company's early reluctance to
invest in research to Sir Harry Jephcott's
conservative attitude towards innovation.
This interpretation is based partly on
Davenport-Hines and Slinn's earlier history,
and partly on interviews with eminent
company scientists, notably Sir David Jack.
Nevertheless, in the 1950s, after "a change
of heart", which Jones never really explains
(p. 113), Glaxo embarked on innovative
research, almost in spite ofitself, while still
under Jephcott's chairmanship. From the
1960s to the 1980s, there followed a period
ofrestructuring, rationalization and whole-
hearted commitment to innovation, to
which Jones attributes the company's
current success.
Unfortunately, the book's structure,
which is both or, rather, neither thematic
nor chronological, means that the thesis
soon becomes lost in the detail. It also
means that the book is difficult to use as a
research tool because the development of
drugs, which has underpinned much of the
company's success, is impossible to follow
without relying heavily on the index. A
more strictly chronological structure might
have given this complex story greater
coherence.
Although one catches glimpses of the
wider economic and political context in
chapters on the Beechams take-over bid and
on government regulation and the market,
Jones makes relatively little reference to the
wider medical context, which might have
helped to explain why in the 1950s the
company began carrying out innovative
research in the fields of steroids and
cephalosporins. Therefore one could dispute
whether the title, The business ofmedicine,
truly reflects the content ofthe book. On
the other hand, Jones succeeds in painting a
vivid picture of the corporate cultures of
Glaxo, characterized by a meritocratic
atmosphere, and of associated companies,
in particular Allen & Hanburys, which
Glaxo acquired in 1958.
There are some minor imperfections:
unlike the organigrams and graphs, which
are included in the text, the tables are at the
end of the book. Moreover, chapter
headings are not accompanied by numbers,
which makes it difficult to relate each
chapter to the table ofcontents. I must also
point out an error: Derek Barton, who
played a major role in the development of
Glaxo's first truly novel medicine, the
topical steroid Betnovate, is referred to as
"D.H.R. Birkbeck", the name ofhis college!
(p. 316).
Despite its faults, pharmaceuticals have
played such an important part in the history
ofmedicine since the Second World War
that Jones's book serves a useful function as
a work ofreference on the history of a
major British pharmaceutical company.
Viviane Quirke,
Oxford Brookes University
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